Compare BLLN & ABG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLLN | ABG |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | 713 | N/A |
| Industry | Medical Specialities | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.8B |
| IPO Year | N/A | 2001 |
| Metric | BLLN | ABG |
|---|---|---|
| Price | $83.95 | $184.77 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 6 |
| Target Price | $126.71 | ★ $244.33 |
| AVG Volume (30 Days) | ★ 575.7K | 297.8K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.88 |
| EPS | N/A | ★ 9.87 |
| Revenue | N/A | ★ $17,999,000,000.00 |
| Revenue This Year | $46.29 | $5.51 |
| Revenue Next Year | $30.14 | $2.53 |
| P/E Ratio | ★ N/A | $19.50 |
| Revenue Growth | N/A | ★ 4.71 |
| 52 Week Low | $61.96 | $184.61 |
| 52 Week High | $138.70 | $274.50 |
| Indicator | BLLN | ABG |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 31.32 |
| Support Level | $79.33 | N/A |
| Resistance Level | $97.36 | $203.36 |
| Average True Range (ATR) | 8.45 | 7.56 |
| MACD | 0.37 | -1.40 |
| Stochastic Oscillator | 35.65 | 4.45 |
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Asbury Automotive Group is a regional collection of automobile dealerships that went public in March 2002. The company operates 171 new-vehicle stores and 39 collision centers. Over 70% of new-vehicle revenue is from luxury and import brands. Asbury also offers third-party financing and insurance products and its own F&I products via Total Care Auto. Asbury operates in 15 states (mostly in Rocky Mountain states, Texas, the Northeast, and Southeast). Asbury store brands include Herb Chambers in the Northeast, McDavid and Park Place in Texas, Koons in the Washington, D.C. area, and the Larry H. Miller brand in the Western US. Asbury generated about $18 billion of revenue in 2025 and is based in the Atlanta area. The firm targets at least $30 billion of revenue sometime around 2030.